Morgan Stanley raises Lazard stock price target on acquisition model

Morgan Stanley slightly raised its Lazard price target to $53 from $52 while keeping an Underweight rating, even as it cut 2026 EPS by 15% to $2.76 and lifted 2027 EPS to $5.26. The firm now assumes Lazard’s Caravel Law acquisition will add roughly $200 million to $300 million of advisory revenue in 2027-2028, offset by higher compensation ratios of 65.5% in 2026 and 62.0% in 2027. Separately, Lazard’s Q1 2026 results were mixed: EPS of $0.42 missed the $0.53 consensus by 20.75%, while revenue of $757 million beat estimates by 7.17%.

Analysis

The key read-through is not the target increase itself, but the widening split between near-term earnings power and longer-dated optionality. Lazard is being valued on a 2027 recovery case while 2026 gets marked down, which is exactly the kind of setup where the stock can look optically cheap yet remain range-bound until advisory momentum and compensation leverage prove out. The acquisition adds a cleaner growth vector, but the market will likely treat it as deferred revenue support rather than immediate EPS accretion because integration and pay-ratio pressure offset a meaningful chunk of the benefit.

Second-order, this is mildly negative for the broader independent advisory group because it reinforces that scale and sector breadth matter more than headline M&A volume. If Caravel Law brings incremental client access and recurring advisory adjacency, rivals with narrower franchise mix may face more pressure on fee realization and talent retention, especially if Lazard uses the deal to deepen cross-sell into private capital and restructuring. The higher comp assumptions also matter: if one firm is signaling that revenue growth requires a bigger labor bill, that caps multiple expansion across the cohort.

The contrarian angle is that consensus may be underpricing the dividend floor and overpricing the permanence of the 2026 reset. A 4%+ yield with a multi-year payout record can dampen downside, but only if free cash flow holds through the compensation step-up; if not, the market could quickly re-rate the name as a low-growth financial with little catalyst until 2027. The sharp EPS revisions suggest the next few quarters are likely more about estimate cuts than price-target lifts, so the stock may be tradeable on sentiment, but not yet investable on fundamentals alone.

Key Decisions for Investors

• Stay tactically underweight LAZ for the next 1-2 quarters; the setup favors estimate churn over multiple expansion, and upside is likely capped until 2026 comp leverage stabilizes.
• For a relative-value expression, long MS/LAZ pairs only if you want to isolate advisory quality and balance-sheet strength; otherwise avoid owning LAZ outright into earnings revisions because the dividend does not offset near-term forecast risk.
• Buy LAZ only on a drawdown toward the mid-$30s or after a confirmed upward revision cycle in advisory revenue; at current levels the risk/reward is asymmetric to the downside if 2026 estimates keep falling.
• Consider a short-dated covered-call structure on an existing LAZ position to harvest the dividend while limiting upside participation, appropriate over the next 1-3 months while sentiment remains neutral.
• Watch for a 2027 guidepost from management on Caravel integration; if pro forma revenue begins to translate into margin stability rather than just top-line lift, re-rate the name toward the 10x multiple case.